Hanna Shevalye

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3814440/publications.pdf

Version: 2024-02-01

33 papers	1,242 citations	331670 21 h-index	395702 33 g-index
33 all docs	33 docs citations	33 times ranked	1539 citing authors

#	Article	IF	Citations
1	Interaction between magnesium and methylglyoxal in diabetic polyneuropathy and neuronal models. Molecular Metabolism, 2021, 43, 101114.	6.5	7
2	Effect of mitoquinone on liver metabolism and steatosis in obese and diabetic rats. Pharmacology Research and Perspectives, 2021, 9, e00701.	2.4	7
3	Characterization of Mice Ubiquitously Overexpressing Human 15-Lipoxygenase-1: Effect of Diabetes on Peripheral Neuropathy and Treatment with Menhaden Oil. Journal of Diabetes Research, 2021, 2021, 1-11.	2.3	5
4	Progressive Loss of Corneal Nerve Fibers and Sensitivity in Rats Modeling Obesity and Type 2 Diabetes Is Reversible with Omega-3 Fatty Acid Intervention: Supporting Cornea Analyses as a Marker for Peripheral Neuropathy and Treatment . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 1367-1384.	2.4	21
5	Effect of mitoquinone (Mito-Q) on neuropathic endpoints in an obese and type 2 diabetic rat model. Free Radical Research, 2020, 54, 311-318.	3.3	19
6	Effect of Early and Late Interventions with Dietary Oils on Vascular and Neural Complications in a Type 2 Diabetic Rat Model. Journal of Diabetes Research, 2019, 2019, 1-12.	2.3	12
7	Determination of peripheral neuropathy in highâ€fat diet fed lowâ€dose streptozotocinâ€treated female C57Bl/6J mice and Sprague–Dawley rats. Journal of Diabetes Investigation, 2018, 9, 1033-1040.	2.4	28
8	Vascular and Neural Complications in Type 2 Diabetic Rats: Improvement by Sacubitril/Valsartan Greater Than Valsartan Alone. Diabetes, 2018, 67, 1616-1626.	0.6	24
9	Effect of dietary oils on peripheral neuropathy-related endpoints in dietary obese rats. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2018, Volume 11, 117-127.	2.4	21
10	Effect of Dietary Content of Menhaden Oil with or without Salsalate on Neuropathic Endpoints in High-Fat-Fed/Low-Dose Streptozotocin-Treated Sprague Dawley Rats. Journal of Diabetes Research, 2018, 2018, 1-9.	2.3	14
11	Impaired Corneal Sensation and Nerve Loss in a Type 2 Rat Model of Chronic Diabetes Is Reversible With Combination Therapy of Menhaden Oil, Î±-Lipoic Acid, and Enalapril. Cornea, 2017, 36, 725-731.	1.7	28
12	Effect of tempol on peripheral neuropathy in diet-induced obese and high-fat fed/low-dose streptozotocin-treated C57Bl6/J mice. Free Radical Research, 2017, 51, 360-367.	3.3	20
13	Early vs. late intervention of high fat/low dose streptozotocin treated C57Bl/6J mice with enalapril, Î±-lipoic acid, menhaden oil or their combination: Effect on diabetic neuropathy related endpoints. Neuropharmacology, 2017, 116, 122-131.	4.1	25
14	Effect of Fish oil Vs. Resolvin D1, E1, Methyl Esters of Resolvins D1 or D2 on Diabetic Peripheral Neuropathy. Journal of Neurology & Neurophysiology, 2017, 08, .	0.1	17
15	Effect of Treatment with Salsalate, Menhaden Oil, Combination of Salsalate and Menhaden Oil, or Resolvin D1 of C57Bl/6J Type 1 Diabetic Mouse on Neuropathic Endpoints. Journal of Nutrition and Metabolism, 2016, 2016, 1-11.	1.8	20
16	Effect of dietâ€induced obesity or type 1 or type 2 diabetes on corneal nerves and peripheral neuropathy in <scp>C57Bl</scp>/<scp>6J</scp> mice. Journal of the Peripheral Nervous System, 2015, 20, 24-31.	3.1	54
17	Effect of enriching the diet with menhaden oil or daily treatment with resolvin D1 on neuropathy in a mouse model of type 2 diabetes. Journal of Neurophysiology, 2015, 114, 199-208.	1.8	74
18	Effect of glycemic control on corneal nerves and peripheral neuropathy in streptozotocinâ€induced diabetic <scp>C57Bl</scp>/<scp>6J</scp> mice. Journal of the Peripheral Nervous System, 2014, 19, 205-217.	3.1	41

#	Article	IF	Citations
19	Peroxynitrite and protein nitration in the pathogenesis of diabetic peripheral neuropathy. Diabetes/Metabolism Research and Reviews, 2014, 30, 669-678.	4.0	67
20	Endoplasmic Reticulum Stress Plays a Key Role in the Pathogenesis of Diabetic Peripheral Neuropathy. Diabetes, 2013, 62, 944-952.	0.6	160
21	Na⁺/H⁺ exchanger 1 inhibition reverses manifestation of peripheral diabetic neuropathy in type 1 diabetic rats. American Journal of Physiology - Endocrinology and Metabolism, 2013, 305, E396-E404.	3.5	19
22	Prediabetic Nephropathy as an Early Consequence of the High-Calorie/High-Fat Diet: Relation to Oxidative Stress. Endocrinology, 2012, 153, 1152-1161.	2.8	35
23	Metanx Alleviates Multiple Manifestations of Peripheral Neuropathy and Increases Intraepidermal Nerve Fiber Density in Zucker Diabetic Fatty Rats. Diabetes, 2012, 61, 2126-2133.	0.6	38
24	Interplay of sorbitol pathway of glucose metabolism, 12/15-lipoxygenase, and mitogen-activated protein kinases in the pathogenesis of diabetic peripheral neuropathy. Biochemical Pharmacology, 2012, 83, 932-940.	4.4	32
25	Baicalein alleviates diabetic peripheral neuropathy through inhibition of oxidativeâ€“nitrosative stress and p38 MAPK activation. Experimental Neurology, 2011, 230, 106-113.	4.1	84
26	Evaluation of PMI-5011, an ethanolic extract of Artemisia dracunculus L., on peripheral neuropathy in streptozotocin-diabetic mice. International Journal of Molecular Medicine, 2011, 27, 299-307.	4.0	27
27	PARP inhibition alleviates diabetes-induced systemic oxidative stress and neural tissue 4-hydroxynonenal adduct accumulation: Correlation with peripheral nerve function. Free Radical Biology and Medicine, 2011, 50, 1400-1409.	2.9	76
28	Poly(ADP-ribose) polymerase (PARP) inhibition counteracts multiple manifestations of kidney disease in long-term streptozotocin-diabetic rat model. Biochemical Pharmacology, 2010, 79, 1007-1014.	4.4	35
29	Role of 12/15-lipoxygenase in nitrosative stress and peripheral prediabetic and diabetic neuropathies. Free Radical Biology and Medicine, 2010, 49, 1036-1045.	2.9	49
30	New Therapeutic and Biomarker Discovery for Peripheral Diabetic Neuropathy: PARP Inhibitor, Nitrotyrosine, and Tumor Necrosis Factor-Î±. Endocrinology, 2010, 151, 2547-2555.	2.8	77
31	Poly(ADP-ribose) polymerase-1 (PARP-1) gene deficiency alleviates diabetic kidney disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 1020-1027.	3.8	36
32	Different Roles of 12/15-Lipoxygenase in Diabetic Large and Small Fiber Peripheral and Autonomic Neuropathies. American Journal of Pathology, 2010, 177, 1436-1447.	3.8	46
33	Poly(Adenosine 5â€²-Diphosphate-Ribose) Polymerase Inhibition Counteracts Multiple Manifestations of Experimental Type 1 Diabetic Nephropathy. Endocrinology, 2009, 150, 5273-5283.	2.8	24